969 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Allegiance Financial Group Advisory Services LLC

Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 969 shares of the biopharmaceutical company’s stock, valued at approximately $228,000.

Other hedge funds have also added to or reduced their stakes in the company. Huntington National Bank raised its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $33,000. Washington Trust Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $42,000. Finally, True Wealth Design LLC raised its stake in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. Piper Sandler reissued an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Raymond James lifted their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. HC Wainwright lifted their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Stock Down 0.5 %

NASDAQ ALNY opened at $243.86 on Thursday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a 50 day moving average of $254.33 and a 200-day moving average of $262.59. The company has a market cap of $31.57 billion, a price-to-earnings ratio of -112.38 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,986 shares of company stock worth $20,397,849. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.